Healthy volunteers test new Long-Acting HIV drug formulations
NCT ID NCT06033547
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study tested two different long-acting versions of the HIV drug cabotegravir in 56 healthy adults. The goal was to see how safe they are and how the body processes them, not to treat HIV. Participants received a single injection, and researchers measured drug levels and side effects over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Austin, Texas, 78744, United States
Conditions
Explore the condition pages connected to this study.